[Treatment of overactive urinary bladder with imperative urinary incontinence in women].
The clinic at the nephrology and urology chair of the State Altai Medical University admitted 40 females aged 20-74 years with overactive bladder (OAB) symptoms and imperative urinary incontinence (IUI) in 2008-2009. The patients were divided into two groups: 20 patients of group 1 received an anticholinesterase drug solifenacin (vesikar) in a dose 5 mg/day; 20 patients of group 2 received combined treatment. The course of treatment lasted for 1-3 months. As shown by the voiding diary and uroflowmetry, vesikar noticeably reduced or eliminated the rate and intensity of imperative voiding. Urodynamic parameters also changed positively. The treatment prolonged voiding time and volume, lowered Qmax. The effect was persistent.
Neĭmark
A I
AI
Riapolova
M V
MV
Mel'nik
M A
MA
D000328:Adult; D000368:Aged; D001521:Behavior Therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D026741:Physical Therapy Modalities; D011812:Quinuclidines / Q000008:administration & dosage / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D053202:Urinary Incontinence, Urge / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D014563:Urodynamics; D055815:Young Adult
D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate